Cyclopharm Limited (“CYC” or the “Company”) is pleased to announce it has successfully completed a share placement (“Placement”) to institutional and sophisticated investors, of approximately 11.5 million new fully paid ordinary shares at $2.60 per share (“Placement Shares”) raising A$30.0 million before costs. The issue price represents a 4.1% discount to CYC’s 1-month volume weighted average share price (VWAP) prior to announcement of the capital raising of $2.71.
The Placement received overwhelming support from new and existing institutional and sophisticated investors including cornerstone participation from leading Australian institutions Perennial Value Management, Investors Mutual and Regal Funds Management.
For more information, download the attached PDF.
Download this document